待处理
入排:排除
图源:待检查
Correction: A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Int J Gynecol Cancer 33(10) 1672
摘要
摘要
无摘要
KM 提取结果
0 个 Figure · 0 个 KM 面板